(±)-Blebbistatin
(Synonyms: (S)Blebbistatin) 目录号 : GC12341(±)-Blebbistatin是一种外消旋体混合物,其中包含(+)-Blebbistatinb和(-)-Blebbistatin(货号:GC13430)两种构型。(±)-Blebbistatin能够有效抑制非肌肉肌球蛋白II ATP酶活性,抑制多种横纹肌肌球蛋白以及脊椎动物非肌肉肌球蛋白表达。
Cas No.:674289-55-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines | Rat ventricular myocytes |
Preparation Method | Fluo-5F–loaded myocytes were placed in an open chamber on an inverted stage microscope with epifluorescence objectives and perfused with physiologic salt-containing solution (PSS) at 0.5mL/min. Cells continuously received either PSS alone or PSS with 0.1, 0.5, 2, or 10µM (±)-Blebbistatin. Each cell was exposed to only one blebbistatin concentration. Contraction and calcium transients ([Ca2+]i) were evaluated at baseline and after 10min of blebbistatin application in steady-state conditions. Cell shortening was recorded using IonOptix Digital Sarcomere Length software (IonOptix). |
Reaction Conditions | 0.1, 0.5, 2, or 10µM; 10min |
Applications | In single rat ventricular cells, (±)-Blebbistatin blocked cell shortening in a dose-dependent manner with an IC50 of 0.43µM. However, even at the highest concentration (10µM), it did not affect the [Ca2+]i. |
Animal experiment [2]: | |
Animal models | Wistar rats |
Preparation Method | Rats were randomly divided into groups that received intravesical instillation of Retinyl acetate (RA) or polysorbate 80 in saline. Three days after, each group was subdivided into groups that received (±)-Blebbistatin intravesically (125nM/kg) or DMSO, and immediately after cystometric assessment was performed. |
Dosage form | 125nM/kg; intravesical instillation |
Applications | (±)-Blebbistatin improves urine storage with no impairment of the voiding function. The significant reduction of the detrusor overactivity index, amplitude of nonvoiding contractions, and frequency of nonvoiding contractions in animals with detrusor overactivity (DO), following (±)-Blebbistatin administration. |
References: |
(±)-Blebbistatin is a racemic mixture containing two configurations, (+)-Blebbistatinb and (-)-Blebbistatin (Cat. No. GC13430). (±)-Blebbistatin can effectively inhibit the activity of non-muscle myosin II ATPase and the expression of various striated muscle myosins and non-muscle myosins in vertebrates[1, 2]. (±)-Blebbistatin is a commonly used excitation-contraction uncoupling agent in cardiovascular physiology[3]. (±)-Blebbistatin is a potential photodynamic drug that can kill cancer cells. Exposure to UV light with a wavelength below 488nm can also lead to rapid inhibition of (±)-Blebbistatin[4].
In vitro, (±)-Blebbistatin (0.1, 0.5, 2, 10μM) treated rat ventricular myocytes for 10min prevented cell shortening in a dose-dependent manner with an IC50 of 0.43μM, but did not affect intracellular calcium transients ([Ca2+]i)[5].
In vivo, (±)-Blebbistatin (125nM/kg) treated rats with detrusor overactivity (DO) by intravesical instillation significantly reduced the detrusor overactivity index, non-micturition contraction amplitude, and non-micturition contraction frequency, and improved urine storage without impairing urination function[6]. (±)-Blebbistatin (125nM/kg) treated DO rats by intra-arterial injection attenuated 13-cis-RA-induced changes in cystometric parameters and central and peripheral neurotrophic factor levels, and also had antidepressant-like effects[7].
References:
[1]Lucas‐Lopez C, Patterson S, Blum T, et al. Absolute Stereochemical Assignment and Fluorescence Tuning of the Small Molecule Tool,(–)‐Blebbistatin[J]. 2005.
[2]Limouze J, Straight A F, Mitchison T, et al. Specificity of blebbistatin, an inhibitor of myosin II[J]. Journal of Muscle Research & Cell Motility, 2004, 25: 337-341.
[3]George S A , Lin Z , Efimov I R .Simultaneous triple-parametric optical mapping of transmembrane potential, intracellular calcium and NADH for cardiac physiology assessment[J].Communications Biology, 2024.
[4]Sakamoto T, Limouze J, Combs C A, et al. Blebbistatin, a myosin II inhibitor, is photoinactivated by blue light[J]. Biochemistry, 2005, 44(2): 584-588.
[5]Fedorov V V, Lozinsky I T, Sosunov E A, et al. Application of blebbistatin as an excitation–contraction uncoupler for electrophysiologic study of rat and rabbit hearts[J]. Heart rhythm, 2007, 4(5): 619-626.
[6]Wróbel A, Nowakowski Ł, Doboszewska U, et al. Blebbistatin reveals beneficial effects on the cystometric parameters in an animal model of detrusor overactivity[J]. Naunyn-schmiedeberg's Archives of Pharmacology, 2019, 392: 843-850.
[7]Wróbel A, Doboszewska U, Rechberger E, et al. Blebbistatin, a myosin II inhibitor, exerts antidepressant-like activity and suppresses detrusor overactivity in an animal model of depression coexisting with overactive bladder[J]. Neurotoxicity Research, 2019, 35: 196-207.
(±)-Blebbistatin是一种外消旋体混合物,其中包含(+)-Blebbistatinb和(-)-Blebbistatin(货号:GC13430)两种构型。(±)-Blebbistatin能够有效抑制非肌肉肌球蛋白II ATP酶活性,抑制多种横纹肌肌球蛋白以及脊椎动物非肌肉肌球蛋白表达[1, 2]。(±)-Blebbistatin是一种心血管生理学中常用的激发-收缩解偶联剂[3]。(±)-Blebbistatin是一种潜在的光动力药物,可以杀死癌细胞,暴露于波长低于488nm的UV光也可导致(±)-Blebbistatin迅速被抑制[4]。
在体外,(±)-Blebbistatin(0.1, 0.5, 2, 10μM)处理大鼠心室肌细胞10min,以剂量依赖性方式阻止细胞缩短,IC50为0.43µM,但不会影响细胞内钙瞬变([Ca2+]i)[5]。
在体内,(±)-Blebbistatin(125nM/kg)通过膀胱灌注治疗患有逼尿肌过度活动(DO)的大鼠,显著降低了逼尿肌过度活动指数、非排尿收缩幅度和非排尿收缩频率,改善尿液储存,而不会损害排尿功能[6]。(±)-Blebbistatin(125nM/kg)通过动脉注射治疗DO大鼠,可减弱13-cis-RA诱导的膀胱测压参数以及中枢和外周神经营养因子水平的变化,还具有抗抑郁样作用[7]。
Cas No. | 674289-55-5 | SDF | |
别名 | (S)Blebbistatin | ||
化学名 | 3a-hydroxy-6-methyl-1-phenyl-3,3a-dihydro-1H-pyrrolo[2,3-b]quinolin-4(2H)-one | ||
Canonical SMILES | OC12CCN(C1=NC3=C(C2=O)C=C(C=C3)C)C4=CC=CC=C4 | ||
分子式 | C18H16N2O2 | 分子量 | 292.34 |
溶解度 | 10mg/mL in DMSO, 20mg/mL in DMF | 储存条件 | Store at -20°C,unstable in solution, ready to use. |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.4207 mL | 17.1034 mL | 34.2067 mL |
5 mM | 0.6841 mL | 3.4207 mL | 6.8413 mL |
10 mM | 0.3421 mL | 1.7103 mL | 3.4207 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。